Table 1. The table shows the patient's age and sex; tumor location, POLE mutation, immunotherapy received; response to treatment; overall survival, and tumor mutational burden.

Abbreviations: NED, no evidence of disease; CR, complete response; PR, partial response

Case no.	Age	Sex	Cancer Location	POLE Mutation	Immunotherapy received	Survival Status	Overall Survival (mos)	Tumor Mutational Burden (TMB; mutations/megabase)	Study
1.	50	Male	Hepatic Flexure	P286	Pembrolizumab	Alive (NED)	>24	295
2.	81	Male	Hepatic Flexure	V411L	Pembrolizumab	Alive (CR)	12	122	Gong et al. [14]
3.	>30	Male	Rectum	P286	Toripalimab	Alive (NED)	12	453	Wen et al. [15]
4.	>70	Male	Ascending Colon	P286	Sintilimab	Alive (NED)	18	255
5.	>20	Male	Sigmoid Colon	P286	Sintilimab	Alive (NED)	7	320
6.	>30	Male	Transverse Colon	P286	Toripalimab	Alive (NED)	14	307
7.	28	Female	Transverse Colon	P286	Ipilimumab + nivolumab	Alive (PR)	-	198	Keenan et al. [12]
8.	37	Male	Ascending Colon	P286	Pembrolizumab	Alive (Significant Response)	>24	168
9.	44	Male	Rectum	V411L	Pembrolizumab	Alive (CR)	>28	200	Silberman et al. [7]
10.	20	Male	Sigmoid Colon	P286	Pembrolizumab	PD	-	-	Wang et al. [16]
11.	34	Male	Cecum	P286	Pembrolizumab	Alive (SD)	>7	-
12.	82	Male	Ascending Colon	V411L	Pembrolizumab	Alive (CR)	>12	-
13.	24	Male	Descending Colon	P286	Pembrolizumab	Alive (CR)	>48	126	Durando et al. [17]
14.	55	Male	Cecum	P436	Pembrolizumab	Alive (CR)	>24	>150	Bikhchandani et al. [18]
15.	16	Male	Transverse and Descending Colon	Ser297Cys* Lynch Syndrome	Nivolumab + anti LGA3	Alive (CR)	>18	530	Berrino et al. [19]
16.	34	Male	Transverse Colon	P286	Terriprizumab and bevacizumab	Alive (PR)	>18	120	Xiang et al. [20]